Another example of a patient subset-specific effect of PDGFRβ inhibition was recently provided in a preclinical study using BRCA1-deficient breast cancer models, where targeted deletion of Pdgfrb suppressed tumorigenesis [144]. Here, PDGFRB is linked to breast carcinoma.